Dag-1 carcinoma cell in studying the mechanisms of progression and therapeutic resistance in bladder cancer.
OBJECTIVE
We describe a new human bladder carcinoma cell line (DAG-1) established from a resected bladder cancer fragment and maintained in culture for more than 5 years and over 300 passages.


RESULTS
Immunological, biochemical and molecular analysis showed that the DAG-1 cells (62 chromosomes) express the cytokeratines 8, 13, 18 and 20 that confirm their epithelial origin as well as numerous cytokine and cytokine receptor mRNAs. They secrete tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA), plasminogen activator inhibitors (PAI-1 and PAI-2), and express u-PA receptors (u-PAR/CD87) at their surface. DAG-1 cells are resistant to TNFalpha- and IFNgamma-induced apoptosis, two cytokines secreted in the urine of Calmette-Guérin bacillus-treated patients and involved in the tumor regression.


CONCLUSIONS
The DAG-1 cell line is a useful tool, both in vitro and in vivo, to study the progression of bladder tumors and their mechanisms of resistance to immunotherapy in relation with PAI-2 and antioxidant enzymes.
Département de Biologie et de Pathologie de la Cellule, Centre Hospitalier Universitaire de Grenoble, Hôpital Albert-Michalon, BP-217, F-38043 Grenoble cedex, France. Pierre.Champelovier@ujf-grenoble.fr
P
P
Champelovier
A
A
Besse
N
N
Boucard
A
A
Simon
D
D
Leroux
N
N
Pinel
V
V
Praloran
D
D
Seigneurin
D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology